Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?
(2023) In Travel Medicine and Infectious Disease 54.- Abstract
Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4ea52021-2404-4b20-b8e1-46385f7f7d5a
- author
- Angelin, Martin ; Sjölin, Jan ; Kahn, Fredrik LU ; Ljunghill Hedberg, Anna ; Rosdahl, Anja ; Skorup, Paul ; Werner, Simon LU ; Woxenius, Susanne and Askling, Helena H.
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Travel Medicine and Infectious Disease
- volume
- 54
- article number
- 102598
- publisher
- Elsevier
- external identifiers
-
- pmid:37271201
- scopus:85161309981
- ISSN
- 1477-8939
- DOI
- 10.1016/j.tmaid.2023.102598
- language
- English
- LU publication?
- yes
- id
- 4ea52021-2404-4b20-b8e1-46385f7f7d5a
- date added to LUP
- 2023-08-17 10:22:24
- date last changed
- 2024-06-16 08:33:44
@article{4ea52021-2404-4b20-b8e1-46385f7f7d5a, abstract = {{<p>Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.</p>}}, author = {{Angelin, Martin and Sjölin, Jan and Kahn, Fredrik and Ljunghill Hedberg, Anna and Rosdahl, Anja and Skorup, Paul and Werner, Simon and Woxenius, Susanne and Askling, Helena H.}}, issn = {{1477-8939}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Travel Medicine and Infectious Disease}}, title = {{Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?}}, url = {{http://dx.doi.org/10.1016/j.tmaid.2023.102598}}, doi = {{10.1016/j.tmaid.2023.102598}}, volume = {{54}}, year = {{2023}}, }